Should you buy TG Therapeutics stock now?
Yes, the technical signal for TG Therapeutics is currently Strong Buy. TG Therapeutics trades at $64.51 as of Nov 14, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 2.526 with rising momentum (signal: 1.874); RSI is at 65.4 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $77.50 points to 20.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for TG Therapeutics stock?
The average analyst price target for TG Therapeutics is $77.50. The current price is $64.51, which gives an upside of 20.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $69.75 and $85.25.
Is TG Therapeutics a dividend stock?
No, TG Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of TG Therapeutics stock?
TG Therapeutics is rated as a stock in the risk category Moderate. the annual standard deviation is 46.1%, which classifies the stock as Moderate.
Is TG Therapeutics overvalued?
No, TG Therapeutics is considered undervalued based on the analyst price target (20.1% upside). TG Therapeutics has the following valuation ratios: a P/E ratio of 96.4 (highly valued), a P/S ratio of 10.9, a P/B ratio of 17.4. The analyst price target suggests that the stock is undervalued by 20.1%.
Is TG Therapeutics overbought?
No, TG Therapeutics is not overbought. RSI is at 65.4 (neutral zone). The technical indicators show: RSI is at 65.4 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 9.4% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next TG Therapeutics earnings report?
TG Therapeutics reports its next earnings on March 1, 2027. The stock currently trades at $64.51. With a P/E ratio of 96.4, the market will be watching closely whether earnings meet expectations. The RSI is at 65.4, so the report can reinforce the current technical trend.
Is TG Therapeutics shorted?
Yes, TG Therapeutics is shorted with 27.7% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying TG Therapeutics stock?
No, insiders are not buying TG Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 274,800 USD worth of shares were sold. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 7,516,953 USD sold. Active sellers include Charney Laurence N, Echelard Yann, Lonial Sagar and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is TG Therapeutics a good stock?
Based on our total score, TG Therapeutics is rated as a mediocre stock with a total score of 59 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 7/100, Quality: 74/100, Momentum: 97/100. In addition: analysts see 20.1% upside to the price target. Whether now is the time to buy is a separate question: the technical signal is Strong Buy. Whether TG Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for TG Therapeutics stock?
The outlook for TG Therapeutics based on current data: the average analyst price target is $77.50 (+20.1%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Mar 1, 2027, which can move the price; the P/E ratio is 96.4 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is TG Therapeutics stock rising?
TG Therapeutics is rising right now. The technical indicators show: the price is 9.4% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 27.7% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can TG Therapeutics go?
The average analyst price target for TG Therapeutics is $77.50, which corresponds to a potential gain of 20.1% from the current price of $64.51. The stock has traded between $26.76 and $68.03 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can TG Therapeutics fall?
The stock has traded as low as $26.76 over the last 52 weeks — that is 58.5% below the current price of $64.51. The biggest decline (drawdown) in the same period was 60.7% from high to low. Within a year, the price typically swings about ±46.1% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does TG Therapeutics do?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal ... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate TG Therapeutics as an investment.
Did TG Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from TG Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is TG Therapeutics making money or losing money?
Yes, TG Therapeutics is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 11.8% — which is solid. The operating margin (profit before interest and taxes) is 21.5%. At a P/E ratio of 96.4, you currently pay 96.4 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can TG Therapeutics go bankrupt?
The bankruptcy risk of TG Therapeutics is rated as low. Altman Z2 (a model for assessing financial distress) is 3.10 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 160% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does TG Therapeutics have a lot of debt?
Yes, TG Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 160%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can TG Therapeutics service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 5.7x, and net debt equals 1.7 years of earnings (EBITDA).